QIBA PET Amyloid Biomarker Committee (BC) Call
12 May 2017 at 9:00 AM CT
Draft Call Summary

In attendance:         RSNA
Anne Smith, PhD  (Co-Chair)     Paul Kinahan, PhD       Amy Perkins, PhD       Joe Koudelik
Ronald Boellaard, PhD     Adriaan Lammertsma, PhD   Na Sun, PhD          Julie Lisiecki
Christopher Buckley, PhD     Dawn Matthews, MS, MBA      Jean-Luc Vanderheyden, PhD
Susan De Santi, PhD       Nancy Obuchowski, PhD     Richard Wahl, MD, FACR

Moderator: Dr. Smith

Status of BC Profile Vote to Release:
• Friday, May 12, 2017 was the deadline for the BC vote
• A majority vote of 7:13 has moved the Profile forward for a Nuclear Medicine Coordinating Committee (NM CC) vote for release
• June 1st is the target date for official release for public comment, pending approval by a majority of the CC

Amyloid BC Updates:
• Groundwork projects are still needed (see below)
• Round-6 funding has been allotted for the DRO, which is important to moving the Profile forward

Feasibility Testing Suggestions:
• More extensive testing at multiple sites is needed
• Some data analysis might be required
• In order to move to the “Technically confirmed stage,” additional funding will likely be needed
• At least 20 datasets will be required for image analysis
• Harmonizing image analysis is critical to the Profile
• For those who will be scanning for feasibility testing, it was recommended that full field of view (FOV) CT reconstruction (e.g. 50 cm) should be used, so an accurate mu-map can be formed for PET attenuation and scatter correction
  • Some images had head holder truncation where this protocol was not followed

Partnership suggestions:
• To aid with funding and moving the Profile forward, it was suggested that partnership opportunities be explored with the following:
  • Aging Institute, NIH and FNIH
  • ADNI
  • AFAR
  • Alzheimer’s Association
  • Drug companies / pharma
  • European initiatives
  • GAAIN

Tau agents:
• Tau agents were suggested as a future addition to the Profile
  • However, tau study is a very fluid field and not mature enough yet for a full Profile
  • Test-retest studies would be needed
• It was suggested that Ms. Matthews repurpose the QIBA Kiosk Amyloid BC poster at the Human Amyloid Imaging Conference (HAI) in Miami this winter to gauge interest in collaborative efforts.

Next Profile Version for PET Brain:
• Update PET Amyloid Profile to include PET / MR
• FDG: Make it more specific and useful for dementia imaging

Action items:
• All are encouraged to provide contact names and emails tailored for the Amyloid BC Profile to RSNA staff for the dissemination list to jlisiecki@rsna.org
• Dr. Perlman to draft an “QIBA introductory” email for organizations that may be unfamiliar with the QIBA initiatives; this was deemed an educational opportunity to showcase QIBA

Parallel tasks
• A testing procedure is needed for conformance: this will follow once the Profile is released for Public Comment
  o Dataset development for conformance testing is needed
• Acquiring data in support of / to enhance the Claim
• Checklist development

NM WebEx Schedule:

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5/19</td>
<td>SPECT BC (cancelled)</td>
<td>6/2</td>
<td>FDG-PET BC</td>
</tr>
<tr>
<td>5/26</td>
<td>NM Leadership (TBD)</td>
<td>6/9</td>
<td>NM Coordinating Ctte</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6/16</td>
<td>SPECT BC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6/23</td>
<td>NM Leadership (TBD)</td>
</tr>
</tbody>
</table>